KRAS G12V Peptide TFA
KRAS G12V Peptide TFA is a polypeptide and epitope derived from KRASG12V. KRAS G12V Peptide TFA forms a stable, high-affinity peptide-HLA class I complex, which is processed and presented by tumor cells and can be recognized by specific TCR. KRAS G12V Peptide TFA is applicable to research related to metastatic lung cancer.
For research use only. We do not sell to patients.
- Purity: 97.01%
- Formula: C40H73N11O11.xC2HF3O2
- Molecular Weight:884.07 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
KRas G12V |
MHC I |
KRAS G12V peptide TFA can be targeted by TCR-engineered CD8+ T cells, which mediate efficient, dose-dependent killing of KRASG12V+ tumor cells; among these, HLA-A*11:01-restricted TCRA11V exhibits faster killing kinetics, which correlates with higher abundance of cell-surface peptide-HLA complexes[1].
KRAS G12V Peptide (1 mM; 2 h pulsed, 16-24 h co-incubation) TFA does not induce cytotoxic activity against KV2 peptide-loaded T2KO-A1101 cells in primary T cells transduced with KDA11-01 and KDA11-02 TCRs[2].
KRAS G12V Peptide (1 mM) TFA does not induce detectable IFN-γ production in primary T cells transduced with KDA11-01 and KDA11-02 TCR[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T2KO-A1101 antigen-presenting cells, KDA11-01/KDA11-02 TCR-transduced primary human T cells
-
Concentration:10-6 M (pulsed for 2 h)
-
Incubation Time:16-24 h (co-incubation with TCR-transduced T cells)
-
Result:Showed negligible cytotoxicity against T2KO-A1101 cells pulsed with KRAS G12V peptide KV2, with cytotoxicity percentages comparable to non-transduced PBMC controls.
Chemical Information
-
Appearance Solid
-
Molecular Weight 884.07 (free base)
-
Formula C40H73N11O11.xC2HF3O2
-
Color White to off-white
-
SMILES
O=C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@@H](C(C)C)C(NCC(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C(C)C)N.OC(C(F)(F)F)=O.[x]
-
Sequence
Val-Val-Val-Gly-Ala-Val-Gly-Val-Gly-Lys
-
Sequence Shortening
VVVGAVGVGK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bear AS, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature communications. 2021 Jul 16;12(1):4365. [Content Brief]
[2]. Zheng W, et al. Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through development. Oncology research. 2024;32(12):1837-1850. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KRAS G12V Peptide TFA Related Classifications
HY-P11356A Related Classifications
Powered by Bioz